BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Baxano Receives CE Mark for iO-Flex® System


3/7/2012 7:19:12 AM

SAN JOSE, Calif.--(BUSINESS WIRE)-- Baxano, Inc., a Silicon Valley-based medical device company and manufacturer of the iO-Flex® System for spinal decompression surgery, announced today that it has received CE Mark approval allowing for future expansion into European markets.

Already FDA cleared, Baxano’s flagship iO-Flex System has rapidly gained interest among US spine and neurosurgeons as the first minimally invasive set of flexible instruments designed to target lumbar stenosis in the central canal, lateral recess, and neural foramen with minimal disruption to the patient’s healthy anatomy critical for maintaining spinal stability. It is the only treatment alternative that allows surgeons to decompress up to four nerve roots through a single laminotomy.

“This is a major milestone for the company,” said Tony Recupero, President & CEO of Baxano. “Although our immediate focus remains supporting our domestic sales demand, we look forward to working with our international surgeon partners and being able to provide their patients suffering from lumbar spinal stenosis a new minimally invasive surgical option.”

Preliminary results from a post market clinical study on the iO-Flex System will be presented by neurosurgeon, Lawrence Dickinson, MD, at the upcoming International Society for the Advancement of Spine Surgery held in Barcelona, Spain, March 20-23rd.

Lumbar Spinal Stenosis is a degenerative medical condition in which the spinal canal narrows and compresses the spinal cord and nerves in the lumbar area of the spine. Symptoms include pain, weakness, numbness, and tingling in the lower back and legs. Decompression surgery is a common procedure used to treat lumbar spinal stenosis by cutting away overgrown bone and tissue causing pressure on the spinal nerves. Approximately 325,000 decompression procedures are performed in the United States each year to treat lumbar spinal stenosis.

For more information about Baxano, the iO-Flex System or the company’s post-market clinical trials, please visit: www.baxano.com or contact media relations representative Paul Williams at 310-569-0023 or paul@medialinecommunications.com.

About Baxano, Inc.

Baxano, Inc., based in San Jose, California, is a privately held company, which was founded in 2005 with the vision to create flexible tools to provide precision lumbar decompression from the “inside out.” These platform technologies will form the basis for future product offerings. Baxano’s mission is to develop innovative tools that restore spine function, preserve healthy tissue, and enable a better quality of life for patients. Along with its dedication to advanced technology development, Baxano is focused on providing exceptional value to patients, customers, investors, and employees.

Caution: Federal law restricts this device to sale by or on the order of a physician. For complete information regarding Intended/Indications for Use, Precautions, Warnings, and potential adverse events, please refer to respective Instructions for Use.

For more information about Baxano and its products, please visit: www.baxano.com

Contact:

For Baxano, Inc.

Paul Williams, 310-569-0023



Read at BioSpace.com

Baxano
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES